Phase 3 Thyroid Eye Disease Clinical Trial Completes Enrollment
According to a story from Business Wire, the biotechnology company Viridian Therapeutics, Inc., has completed its enrollment goal for its phase 3 clinical trial designated THRIVE-2. This clinical trial will…